Tesamorelin: Mechanistic Overview
internal_protocolestablished · status: needs_provider_reviewDetails
Author: Axiom Knowledge Base
Citation: Internal reference summary compiled for the Axiom knowledge base (2026).
File: signed link
Summary (generated — provider review required)
Tesamorelin is a growth-hormone-releasing-hormone (GHRH) analog, FDA-approved for HIV-associated lipodystrophy. Mechanism: stimulates endogenous GH/IGF-1 release. Relevance: metabolic and body-composition contexts; cognitive effects studied.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (4) · phenotypes (0)
evidence_reference, mechanism, contraindication_reference, dosing_reference
Findings (4) · awaiting review (3)
regulatory · pending
Tesamorelin is a growth-hormone-releasing-hormone (GHRH) analog, FDA-approved for HIV-associated lipodystrophy.
mechanism · pending
Mechanism: stimulates endogenous GH/IGF-1 release.
contraindication · pending
Safety: contraindicated in active malignancy and pregnancy; monitor glucose/IGF-1 — these are physician-managed considerations.
dosing · pending
Background for provider review only — not a treatment recommendation or dosing guidance.
Processing
Processed into 1 searchable section.